You are here: All Products  > BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal

BioSense Acquires China Rights to Rexahn's Pancreatic Cancer Drug in $226 Million Deal

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products